Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

FATE THERAPEUTICS INC

FATE · Nasdaq · CIK 0001434316 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
4 sales · 4 option, withholding, award, gift or other lines

Last qualifying purchase2024-12-20 · Green Jeremy; Redmile Group, LLC · $668.6K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
TAHL CINDYSee Remarks
○▼▼
Valamehr BahramPresident and CEO
▼▼
EPSTEIN ROBERT SDirector
○
RASTETTER WILLIAM HDirector
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-20 · Green Jeremy; Redmile Group, LLC.

Recent Form 4 activity

0Purchases
6Sales
9Other Form 4 lines
14SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING4 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
10,759,313
Previous report
9,386,451
Avg daily volume
2,041,291
Days to cover
5.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-12-20Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock397,964USD 1.68USD 668,580SEC filing ↗
2023-12-26Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock44,630USD 3.72USD 166,024SEC filing ↗
2023-04-21Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock256,639USD 6.18USD 1,586,029SEC filing ↗
2023-04-20Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock20,000USD 5.99USD 119,800SEC filing ↗
2023-04-14Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock25,700USD 6.00USD 154,200SEC filing ↗
2023-01-13MENDLEIN JOHNPurchase (P)Common Stock36,631USD 5.43USD 198,906SEC filing ↗
2023-01-11MENDLEIN JOHNPurchase (P)Common Stock88,048USD 5.67USD 499,232SEC filing ↗
2021-01-08Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock327,485USD 85.50USD 27,999,968SEC filing ↗
2020-06-11Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock1,412,928USD 28.31USD 39,999,992SEC filing ↗

Form 4 evidence

15 transaction lines in the latest 365-day window; 393 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Valamehr BahramSale (S)Common Stock43,947USD 2.46USD 108,110SEC filing ↗
2026-08-04TAHL CINDYSale (S)Common Stock38,800USD 2.46USD 95,448SEC filing ↗
2026-05-20Valamehr BahramSale (S)Common Stock28,946USD 1.88USD 54,418SEC filing ↗
Show recent Form 4 evidence (14 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Valamehr BahramSale (S)Common Stock43,947USD 2.46USD 108,110SEC filing ↗
2026-08-04TAHL CINDYSale (S)Common Stock38,800USD 2.46USD 95,448SEC filing ↗
2026-05-20Valamehr BahramSale (S)Common Stock28,946USD 1.88USD 54,418SEC filing ↗
2026-05-20TAHL CINDYSale (S)Common Stock25,590USD 1.88USD 48,109SEC filing ↗
2026-05-06TAHL CINDYOption exercise / conversion (M)Common Stock166,664USD 1.25USD 207,997SEC filing ↗
2026-05-05RASTETTER WILLIAM HOption exercise / conversion (M)Common Stock25,000USD 1.69USD 42,250SEC filing ↗
2026-05-05EPSTEIN ROBERT SOption exercise / conversion (M)Common Stock25,000USD 1.69USD 42,250SEC filing ↗
2026-04-20Green Jeremy; RedCo II Master Fund, L.P.; Redmile Group, LLCJ (J)Common Stock8,977,624USD 0.00USD 0SEC filing ↗
2026-01-15Valamehr BahramAward / grant (A)Common Stock335,000USD 0.00USD 0SEC filing ↗
2026-01-15TAHL CINDYAward / grant (A)Common Stock100,000USD 0.00USD 0SEC filing ↗
2026-01-15Adawi KamalAward / grant (A)Common Stock25,000USD 0.00USD 0SEC filing ↗
2026-01-09Valamehr BahramSale (S)Common Stock5,190USD 1.07USD 5,553SEC filing ↗
2026-01-09TAHL CINDYSale (S)Common Stock10,589USD 1.06USD 11,224SEC filing ↗
2025-10-20Adawi KamalAward / grant (A)Common Stock75,000USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerFATE
CIK0001434316
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history393 transaction lines from 2020-01-08 to 2026-08-04
9 P purchase lines · 254 S sale lines · 130 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.